BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis AG (NVS) Stops Developing Long-Acting Version of Vanda Pharmaceuticals, Inc. (VNDA)'s Fanapt


10/12/2012 8:39:35 AM

Washington Business Journal by Bill Flook, Staff Reporter

Novartis Pharma AG is discontinuing development on a long-acting injectable version of Vanda Pharmaceuticals Inc.’s Fanapt, the District-based biotech reported in a securities filing.

Novartis has marketed Fanapt, a schizophrenia drug and Vanda’s lead product, since 2010. The pharma giant has exclusive rights to develop and commercialize other formulations of Fanapt in the U.S. and Canada, as well. But in a blow to the local drugmaker, Novartis gave word on Oct. 8 that it would cease development on the long-acting “depot” formulation, according to Vanda’s filing, which did not give an explanation for the program’s demise.

The original version of Fanapt won a surprise approval in 2009, but sluggish sales have not lived up to the original enthusiasm. The company posted a net loss of $8 million in the second quarter of 2012, up from $1.3 million in the same period last year. Revenue in the quarter did, however, grow to $8.4 million on higher Fanapt royalty payments.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES